Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions
Identification of regulatory T cells (Tregs) has led to breaking the dichotomy of the Th1/Th2 axis in the immunopathology of several diseases such as autoimmune diseases and cancer. Despite the presence of extensive information about immunobiology of Tregs in pathogenesis of autoimmune diseases, lit...
Gespeichert in:
| Veröffentlicht in: | Tumor biology 2013-08, Vol.34 (4), p.2031-2039 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2039 |
|---|---|
| container_issue | 4 |
| container_start_page | 2031 |
| container_title | Tumor biology |
| container_volume | 34 |
| creator | Jadidi-Niaragh, Farhad Ghalamfarsa, Ghasem Yousefi, Mehdi Tabrizi, Mina Hajifaraj Shokri, Fazel |
| description | Identification of regulatory T cells (Tregs) has led to breaking the dichotomy of the Th1/Th2 axis in the immunopathology of several diseases such as autoimmune diseases and cancer. Despite the presence of extensive information about immunobiology of Tregs in pathogenesis of autoimmune diseases, little is known about the frequency and function of these cells in hematologic malignancies, particularly chronic lymphocytic leukemia (CLL). Recent data have demonstrated increased frequency and intact functional capacity of CD4
+
Tregs in CLL patients. However, the precise role of these cells in the immunopathology of CLL is not well known. While targeting Tregs in cancer diseases seems to be an interesting immunotherapeutic approach, such therapeutic interventions in CLL might be deleterious due to suppression of the tumor-specific adaptive and innate immune responses. Thus, the precise biological and regulatory functions of all Tregs subsets should be carefully investigated before planning any immunotherapeutic interventions based on targeting of Tregs. In this communication, we review the recent data published on immunobiology of Tregs in CLL and discuss about the possibility of targeting Tregs in CLL. |
| doi_str_mv | 10.1007/s13277-013-0832-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1430848229</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1401092174</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-6a3bdc1685048ef17f1714b8f9ba6d79c92c8c57daa4943ef9809dcbae6930123</originalsourceid><addsrcrecordid>eNqNkV1LHTEQhkOp1I_2B3gjC73xZmsmydlNelfE1oIgiF6HbHbWE7ubrMmueP69WY4WEQRhYGbIM2-YeQk5BPoDKK1PEnBW1yUFXlLJWfn4ieyBYLnjkn7ONQVaCib5LtlP6Y5SWClVfSG7jFcSaiX3iL3C27k3U4ib4rqw2PepcL6w6xi8s0W_GcZ1sJtpqXH-h4MzPws3jL2zZnLBF12IuR9mH6Y1RjPivLDOTxgf0C9I-kp2OtMn_PacD8jN77Pr0_Py4vLP39NfF6UVdDWVleFNa6GSKyokdlDnANHITjWmamtlFbPSrurWGKEEx05JqlrbGKwUp8D4ATne6o4x3M-YJj24tKxkPIY5aRCcSiEZUx9A8-kUg1pk9Psb9C7M0edFFipfWjBYBGFL2RhSitjpMbrBxI0Gqhez9NYsnc3Si1n6Mc8cPSvPzYDt_4kXdzLAtkDKT_4W46uv31V9AkWIoNY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1400384219</pqid></control><display><type>article</type><title>Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions</title><source>MEDLINE</source><source>SpringerLink Journals (MCLS)</source><creator>Jadidi-Niaragh, Farhad ; Ghalamfarsa, Ghasem ; Yousefi, Mehdi ; Tabrizi, Mina Hajifaraj ; Shokri, Fazel</creator><creatorcontrib>Jadidi-Niaragh, Farhad ; Ghalamfarsa, Ghasem ; Yousefi, Mehdi ; Tabrizi, Mina Hajifaraj ; Shokri, Fazel</creatorcontrib><description>Identification of regulatory T cells (Tregs) has led to breaking the dichotomy of the Th1/Th2 axis in the immunopathology of several diseases such as autoimmune diseases and cancer. Despite the presence of extensive information about immunobiology of Tregs in pathogenesis of autoimmune diseases, little is known about the frequency and function of these cells in hematologic malignancies, particularly chronic lymphocytic leukemia (CLL). Recent data have demonstrated increased frequency and intact functional capacity of CD4
+
Tregs in CLL patients. However, the precise role of these cells in the immunopathology of CLL is not well known. While targeting Tregs in cancer diseases seems to be an interesting immunotherapeutic approach, such therapeutic interventions in CLL might be deleterious due to suppression of the tumor-specific adaptive and innate immune responses. Thus, the precise biological and regulatory functions of all Tregs subsets should be carefully investigated before planning any immunotherapeutic interventions based on targeting of Tregs. In this communication, we review the recent data published on immunobiology of Tregs in CLL and discuss about the possibility of targeting Tregs in CLL.</description><identifier>ISSN: 1010-4283</identifier><identifier>EISSN: 1423-0380</identifier><identifier>DOI: 10.1007/s13277-013-0832-x</identifier><identifier>PMID: 23681798</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; CD4-CD8 Ratio ; CD8-Positive T-Lymphocytes - immunology ; Disease Progression ; Humans ; Immunotherapy ; Leukemia ; Leukemia, Lymphocytic, Chronic, B-Cell - immunology ; Leukemia, Lymphocytic, Chronic, B-Cell - therapy ; Lymphocytes ; Pathology ; Review ; T-Lymphocytes, Regulatory - immunology</subject><ispartof>Tumor biology, 2013-08, Vol.34 (4), p.2031-2039</ispartof><rights>International Society of Oncology and BioMarkers (ISOBM) 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-6a3bdc1685048ef17f1714b8f9ba6d79c92c8c57daa4943ef9809dcbae6930123</citedby><cites>FETCH-LOGICAL-c405t-6a3bdc1685048ef17f1714b8f9ba6d79c92c8c57daa4943ef9809dcbae6930123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13277-013-0832-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13277-013-0832-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23681798$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jadidi-Niaragh, Farhad</creatorcontrib><creatorcontrib>Ghalamfarsa, Ghasem</creatorcontrib><creatorcontrib>Yousefi, Mehdi</creatorcontrib><creatorcontrib>Tabrizi, Mina Hajifaraj</creatorcontrib><creatorcontrib>Shokri, Fazel</creatorcontrib><title>Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions</title><title>Tumor biology</title><addtitle>Tumor Biol</addtitle><addtitle>Tumour Biol</addtitle><description>Identification of regulatory T cells (Tregs) has led to breaking the dichotomy of the Th1/Th2 axis in the immunopathology of several diseases such as autoimmune diseases and cancer. Despite the presence of extensive information about immunobiology of Tregs in pathogenesis of autoimmune diseases, little is known about the frequency and function of these cells in hematologic malignancies, particularly chronic lymphocytic leukemia (CLL). Recent data have demonstrated increased frequency and intact functional capacity of CD4
+
Tregs in CLL patients. However, the precise role of these cells in the immunopathology of CLL is not well known. While targeting Tregs in cancer diseases seems to be an interesting immunotherapeutic approach, such therapeutic interventions in CLL might be deleterious due to suppression of the tumor-specific adaptive and innate immune responses. Thus, the precise biological and regulatory functions of all Tregs subsets should be carefully investigated before planning any immunotherapeutic interventions based on targeting of Tregs. In this communication, we review the recent data published on immunobiology of Tregs in CLL and discuss about the possibility of targeting Tregs in CLL.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>CD4-CD8 Ratio</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Disease Progression</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Leukemia</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - immunology</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</subject><subject>Lymphocytes</subject><subject>Pathology</subject><subject>Review</subject><subject>T-Lymphocytes, Regulatory - immunology</subject><issn>1010-4283</issn><issn>1423-0380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkV1LHTEQhkOp1I_2B3gjC73xZmsmydlNelfE1oIgiF6HbHbWE7ubrMmueP69WY4WEQRhYGbIM2-YeQk5BPoDKK1PEnBW1yUFXlLJWfn4ieyBYLnjkn7ONQVaCib5LtlP6Y5SWClVfSG7jFcSaiX3iL3C27k3U4ib4rqw2PepcL6w6xi8s0W_GcZ1sJtpqXH-h4MzPws3jL2zZnLBF12IuR9mH6Y1RjPivLDOTxgf0C9I-kp2OtMn_PacD8jN77Pr0_Py4vLP39NfF6UVdDWVleFNa6GSKyokdlDnANHITjWmamtlFbPSrurWGKEEx05JqlrbGKwUp8D4ATne6o4x3M-YJj24tKxkPIY5aRCcSiEZUx9A8-kUg1pk9Psb9C7M0edFFipfWjBYBGFL2RhSitjpMbrBxI0Gqhez9NYsnc3Si1n6Mc8cPSvPzYDt_4kXdzLAtkDKT_4W46uv31V9AkWIoNY</recordid><startdate>20130801</startdate><enddate>20130801</enddate><creator>Jadidi-Niaragh, Farhad</creator><creator>Ghalamfarsa, Ghasem</creator><creator>Yousefi, Mehdi</creator><creator>Tabrizi, Mina Hajifaraj</creator><creator>Shokri, Fazel</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20130801</creationdate><title>Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions</title><author>Jadidi-Niaragh, Farhad ; Ghalamfarsa, Ghasem ; Yousefi, Mehdi ; Tabrizi, Mina Hajifaraj ; Shokri, Fazel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-6a3bdc1685048ef17f1714b8f9ba6d79c92c8c57daa4943ef9809dcbae6930123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>CD4-CD8 Ratio</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Disease Progression</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Leukemia</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - immunology</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</topic><topic>Lymphocytes</topic><topic>Pathology</topic><topic>Review</topic><topic>T-Lymphocytes, Regulatory - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jadidi-Niaragh, Farhad</creatorcontrib><creatorcontrib>Ghalamfarsa, Ghasem</creatorcontrib><creatorcontrib>Yousefi, Mehdi</creatorcontrib><creatorcontrib>Tabrizi, Mina Hajifaraj</creatorcontrib><creatorcontrib>Shokri, Fazel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Tumor biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jadidi-Niaragh, Farhad</au><au>Ghalamfarsa, Ghasem</au><au>Yousefi, Mehdi</au><au>Tabrizi, Mina Hajifaraj</au><au>Shokri, Fazel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions</atitle><jtitle>Tumor biology</jtitle><stitle>Tumor Biol</stitle><addtitle>Tumour Biol</addtitle><date>2013-08-01</date><risdate>2013</risdate><volume>34</volume><issue>4</issue><spage>2031</spage><epage>2039</epage><pages>2031-2039</pages><issn>1010-4283</issn><eissn>1423-0380</eissn><abstract>Identification of regulatory T cells (Tregs) has led to breaking the dichotomy of the Th1/Th2 axis in the immunopathology of several diseases such as autoimmune diseases and cancer. Despite the presence of extensive information about immunobiology of Tregs in pathogenesis of autoimmune diseases, little is known about the frequency and function of these cells in hematologic malignancies, particularly chronic lymphocytic leukemia (CLL). Recent data have demonstrated increased frequency and intact functional capacity of CD4
+
Tregs in CLL patients. However, the precise role of these cells in the immunopathology of CLL is not well known. While targeting Tregs in cancer diseases seems to be an interesting immunotherapeutic approach, such therapeutic interventions in CLL might be deleterious due to suppression of the tumor-specific adaptive and innate immune responses. Thus, the precise biological and regulatory functions of all Tregs subsets should be carefully investigated before planning any immunotherapeutic interventions based on targeting of Tregs. In this communication, we review the recent data published on immunobiology of Tregs in CLL and discuss about the possibility of targeting Tregs in CLL.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>23681798</pmid><doi>10.1007/s13277-013-0832-x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1010-4283 |
| ispartof | Tumor biology, 2013-08, Vol.34 (4), p.2031-2039 |
| issn | 1010-4283 1423-0380 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1430848229 |
| source | MEDLINE; SpringerLink Journals (MCLS) |
| subjects | Biomedical and Life Sciences Biomedicine Cancer Research CD4-CD8 Ratio CD8-Positive T-Lymphocytes - immunology Disease Progression Humans Immunotherapy Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - immunology Leukemia, Lymphocytic, Chronic, B-Cell - therapy Lymphocytes Pathology Review T-Lymphocytes, Regulatory - immunology |
| title | Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T17%3A01%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Regulatory%20T%20cells%20in%20chronic%20lymphocytic%20leukemia:%20implication%20for%20immunotherapeutic%20interventions&rft.jtitle=Tumor%20biology&rft.au=Jadidi-Niaragh,%20Farhad&rft.date=2013-08-01&rft.volume=34&rft.issue=4&rft.spage=2031&rft.epage=2039&rft.pages=2031-2039&rft.issn=1010-4283&rft.eissn=1423-0380&rft_id=info:doi/10.1007/s13277-013-0832-x&rft_dat=%3Cproquest_cross%3E1401092174%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1400384219&rft_id=info:pmid/23681798&rfr_iscdi=true |